Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Colorectal Neoplasms 7Prostatic Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Melanoma 5Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neoplasms 4Small Cell Lung Carcinoma 3Recurrence 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Recurrent Squamous Cell Lung Carcinoma 2Ovarian Neoplasms 2Mesothelioma 2Lung Neoplasms 2Liver Neoplasms 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Vascular Neoplasms 1Uterine Cervical Neoplasms 1Urothelial Cancer 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Testicular Neoplasms 1Solid Tumor 1Sarcoma, Synovial 1

Interventions

tremelimumab 1durvalumab 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Anatomic Stage II Breast Cancer AJCC v8 × tremelimumab × Clear all
NCT03132467 2024-06-05

Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Completed
16 enrolled 8 charts
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡